Earlier this week we highlighted how click chemistry technology has enabled the development of a protodrug platform with inert polymers for more targeted delivery of chemotherapeutic drugs.
Similarly, another related approach we can consider to reduce unwanted adverse events is the prodrug concept. In this situation, a potent chemotherapy is activated in the tumour where it is most needed thereby reducing the toxic effects on normal cells and improving tolerability for people receiving the therapy.
One of the well known challenges and limitations associated with standard alkylating chemotherapies has always been the indiscriminate toxicities resulting from systemic administration – they impact both cancer cells and normal cells with impunity.
What if we could develop a more targeted chemotherapy approach?
This might be useful for some people with advanced cancer where a modicum of disease control is needed, so how would we go about achieving this aim?
Here’s one way to potentially accomplish the task…